Literature DB >> 2154436

In-vitro and in-vivo susceptibility of Borrelia burgdorferi to azithromycin.

R C Johnson1, C Kodner, M Russell, D Girard.   

Abstract

The in-vitro and in-vivo susceptibility of Borrelia burgdorferito tetracycline, erythromycin and azithromycin was investigated. A macrodilution broth technique was used to determine MBCs. B. burgdorferi was most susceptible to azithromycin (MBC 0.04 mg/l) followed by erythromycin (MBC 0.16 mg/l) and tetracycline (MBC 1.6 mg/l). Syrian hamsters were used to determine ED50S for the three antimicrobials. Azithromycin was most effective in the elimination of spirochaetes from experimentally infected hamsters with an ED50 of 3.71 (+/- 1.9) mg/kg followed by tetracycline (ED50 15.6 (+/- 4.58) mg/kg). Erythromycin possessed low activity, having an ED50 of 122.2 (+/- 51.9) mg/kg. Tissue concentrations of azithromycin exceeding the MBC were present 24 h after the final treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2154436     DOI: 10.1093/jac/25.suppl_a.33

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  19 in total

Review 1.  The activity of azithromycin in animal models of infection.

Authors:  J C Pechère
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

2.  Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents.

Authors:  R C Johnson; C B Kodner; P J Jurkovich; J J Collins
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 3.  Antibiotic treatment of animals infected with Borrelia burgdorferi.

Authors:  Gary P Wormser; Ira Schwartz
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

Review 4.  Spectrum of activity of azithromycin.

Authors:  J D Williams
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

5.  Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo.

Authors:  J Alder; M Mitten; K Jarvis; P Gupta; J Clement
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

6.  Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans.

Authors:  F Strle; V Maraspin; S Lotric-Furlan; E Ruzić-Sabljić; J Cimperman
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

7.  In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents.

Authors:  J M Levin; J A Nelson; J Segreti; B Harrison; C A Benson; F Strle
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

8.  Clarithromycin in treatment of early Lyme disease: a pilot study.

Authors:  R J Dattwyler; E Grunwaldt; B J Luft
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

9.  Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice.

Authors:  K D Moody; R L Adams; S W Barthold
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies.

Authors:  L L Dever; J H Jorgensen; A G Barbour
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.